Angeliki Angelidi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastrointestinal Hormones | 2 | 2024 | 101 | 0.990 |
Why?
|
Bariatric Surgery | 3 | 2024 | 992 | 0.970 |
Why?
|
Diet, Mediterranean | 2 | 2022 | 740 | 0.920 |
Why?
|
Lipodystrophy | 2 | 2022 | 145 | 0.860 |
Why?
|
Homeodomain Proteins | 2 | 2022 | 2418 | 0.810 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2022 | 738 | 0.690 |
Why?
|
Anti-Obesity Agents | 1 | 2022 | 227 | 0.630 |
Why?
|
Gastric Bypass | 2 | 2024 | 818 | 0.580 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2024 | 12149 | 0.530 |
Why?
|
Obesity, Morbid | 2 | 2024 | 1277 | 0.490 |
Why?
|
Neoplasm Metastasis | 2 | 2022 | 4915 | 0.460 |
Why?
|
Oxyntomodulin | 2 | 2022 | 8 | 0.410 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6938 | 0.390 |
Why?
|
Obesity | 7 | 2024 | 12947 | 0.380 |
Why?
|
Insulin Resistance | 3 | 2021 | 3964 | 0.370 |
Why?
|
Prediabetic State | 2 | 2014 | 545 | 0.370 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 1388 | 0.370 |
Why?
|
Glucagon | 2 | 2022 | 532 | 0.340 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2630 | 0.330 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3617 | 0.330 |
Why?
|
Adipose Tissue | 1 | 2021 | 3313 | 0.320 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 8553 | 0.320 |
Why?
|
Vitamin D | 1 | 2021 | 3303 | 0.280 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5368 | 0.270 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15843 | 0.260 |
Why?
|
Liver Neoplasms | 1 | 2022 | 4317 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3086 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3206 | 0.250 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 5841 | 0.240 |
Why?
|
Endothelial Cells | 2 | 2014 | 3549 | 0.230 |
Why?
|
Stem Cells | 2 | 2014 | 3524 | 0.230 |
Why?
|
Female Athlete Triad Syndrome | 1 | 2024 | 62 | 0.220 |
Why?
|
Acetoacetates | 1 | 2022 | 19 | 0.210 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2022 | 74 | 0.210 |
Why?
|
Citrates | 1 | 2022 | 134 | 0.210 |
Why?
|
Gastrectomy | 2 | 2024 | 672 | 0.190 |
Why?
|
Weight Loss | 2 | 2022 | 2684 | 0.180 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 370 | 0.170 |
Why?
|
Carbohydrates | 1 | 2022 | 390 | 0.170 |
Why?
|
Proglucagon | 3 | 2024 | 32 | 0.160 |
Why?
|
New York | 1 | 2021 | 874 | 0.150 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 362 | 0.150 |
Why?
|
Lipoproteins | 1 | 2022 | 881 | 0.150 |
Why?
|
Signal Transduction | 1 | 2021 | 23447 | 0.150 |
Why?
|
Hyperlipidemias | 1 | 2022 | 771 | 0.140 |
Why?
|
Humans | 24 | 2024 | 761578 | 0.140 |
Why?
|
Receptor, Insulin | 1 | 2021 | 836 | 0.140 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15502 | 0.130 |
Why?
|
Liver Diseases | 1 | 2024 | 1297 | 0.130 |
Why?
|
Metabolic Diseases | 1 | 2022 | 683 | 0.130 |
Why?
|
Down-Regulation | 1 | 2022 | 2919 | 0.120 |
Why?
|
Syndrome | 1 | 2021 | 3267 | 0.120 |
Why?
|
Insulin Infusion Systems | 1 | 2016 | 217 | 0.120 |
Why?
|
Glucose | 2 | 2022 | 4347 | 0.110 |
Why?
|
Energy Metabolism | 1 | 2024 | 2882 | 0.110 |
Why?
|
Extracellular Matrix Proteins | 1 | 2017 | 829 | 0.110 |
Why?
|
Up-Regulation | 1 | 2022 | 4125 | 0.100 |
Why?
|
Glicentin | 2 | 2022 | 11 | 0.100 |
Why?
|
Lipoprotein(a) | 1 | 2017 | 480 | 0.100 |
Why?
|
Calcium-Binding Proteins | 1 | 2017 | 1069 | 0.100 |
Why?
|
Pandemics | 3 | 2020 | 8656 | 0.100 |
Why?
|
Nutritional Status | 1 | 2020 | 1615 | 0.100 |
Why?
|
Antigens, CD34 | 1 | 2014 | 658 | 0.100 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3769 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 546 | 0.090 |
Why?
|
Homeostasis | 1 | 2022 | 3323 | 0.090 |
Why?
|
Peptides | 3 | 2022 | 4358 | 0.090 |
Why?
|
Cohort Studies | 3 | 2022 | 41493 | 0.090 |
Why?
|
Risk Factors | 5 | 2024 | 74212 | 0.090 |
Why?
|
Biopsy | 1 | 2022 | 6766 | 0.080 |
Why?
|
Liver | 2 | 2024 | 7527 | 0.080 |
Why?
|
Drug Monitoring | 1 | 2016 | 962 | 0.080 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2022 | 364 | 0.080 |
Why?
|
Diabetes Complications | 1 | 2016 | 1315 | 0.080 |
Why?
|
Arginine | 1 | 2012 | 934 | 0.080 |
Why?
|
Intra-Abdominal Fat | 1 | 2014 | 613 | 0.080 |
Why?
|
Insulin | 2 | 2021 | 6597 | 0.080 |
Why?
|
Hypoglycemia | 1 | 2016 | 883 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2020 | 1852 | 0.080 |
Why?
|
Femoral Artery | 1 | 2012 | 826 | 0.080 |
Why?
|
Pyoderma Gangrenosum | 1 | 2009 | 84 | 0.080 |
Why?
|
Carotid Arteries | 1 | 2012 | 941 | 0.080 |
Why?
|
Adult | 6 | 2024 | 221200 | 0.070 |
Why?
|
Middle Aged | 7 | 2022 | 220917 | 0.070 |
Why?
|
Hyperglycemia | 1 | 2016 | 1376 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5293 | 0.070 |
Why?
|
Glycoproteins | 1 | 2014 | 2203 | 0.070 |
Why?
|
Cell Proliferation | 1 | 2022 | 10451 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2118 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10508 | 0.060 |
Why?
|
Animals | 3 | 2022 | 168475 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2905 | 0.060 |
Why?
|
Disease Progression | 1 | 2022 | 13510 | 0.060 |
Why?
|
Female | 8 | 2024 | 392688 | 0.060 |
Why?
|
Adiposity | 1 | 2014 | 1879 | 0.060 |
Why?
|
Prognosis | 1 | 2024 | 29629 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12059 | 0.050 |
Why?
|
Antigens, CD | 1 | 2014 | 4001 | 0.050 |
Why?
|
Fasting | 2 | 2022 | 1603 | 0.050 |
Why?
|
Male | 9 | 2022 | 360841 | 0.050 |
Why?
|
Odds Ratio | 1 | 2014 | 9646 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2016 | 3415 | 0.050 |
Why?
|
Lipids | 2 | 2022 | 3341 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10721 | 0.050 |
Why?
|
Aged | 6 | 2022 | 169308 | 0.040 |
Why?
|
C-Peptide | 1 | 2022 | 440 | 0.040 |
Why?
|
Logistic Models | 1 | 2014 | 13255 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 26127 | 0.040 |
Why?
|
Coffee | 1 | 2022 | 593 | 0.040 |
Why?
|
Caffeine | 1 | 2022 | 700 | 0.040 |
Why?
|
Mutation | 1 | 2022 | 30054 | 0.040 |
Why?
|
Aged, 80 and over | 1 | 2022 | 58983 | 0.030 |
Why?
|
HIV Infections | 1 | 2022 | 17352 | 0.030 |
Why?
|
Water | 1 | 2022 | 1411 | 0.030 |
Why?
|
Greece | 1 | 2016 | 340 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2022 | 36426 | 0.030 |
Why?
|
Diastole | 1 | 2016 | 782 | 0.030 |
Why?
|
Leptin | 1 | 2022 | 1597 | 0.030 |
Why?
|
Hospitals, Urban | 1 | 2016 | 500 | 0.030 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2016 | 395 | 0.030 |
Why?
|
Echocardiography, Doppler | 1 | 2016 | 897 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2021 | 80646 | 0.020 |
Why?
|
Overweight | 1 | 2022 | 2417 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2016 | 1039 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2012 | 1178 | 0.020 |
Why?
|
Triglycerides | 1 | 2016 | 2461 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15266 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22176 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2016 | 3826 | 0.010 |
Why?
|
Echocardiography | 1 | 2016 | 4989 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2012 | 2382 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2016 | 3085 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 2242 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5872 | 0.010 |
Why?
|
Diet | 1 | 2020 | 8075 | 0.010 |
Why?
|
Prospective Studies | 2 | 2016 | 54423 | 0.010 |
Why?
|
Atherosclerosis | 1 | 2017 | 3407 | 0.010 |
Why?
|
Blood Glucose | 1 | 2012 | 6391 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39107 | 0.010 |
Why?
|
United States | 1 | 2020 | 72335 | 0.010 |
Why?
|
Risk Assessment | 1 | 2012 | 23996 | 0.010 |
Why?
|